文献速递真实世界研究与卫生经济新药、器械与细胞基因治疗研发

美国生物制品与小分子药物的法律保护差异

Differential Legal Protections for Biologics vs Small-Molecule Drugs in the US.
PubMed 文献 · JAMA · 2024-01-01

该综述分析美国生物制品与小分子药物在开发时间、临床试验成功率、研发成本、专利保护、市场独占期、收入和治疗成本方面的经验证据,发现生物制品在开发时间、研发成本上与后者无显著差异,但专利数和市场独占期更长,收入和治疗成本更高。结论认为几乎没有证据支持生物制品应享有更长的市场独占期或价格谈判豁免,美国法律似乎相对过度奖励生物制品的开发。

要点

  • 2009-2023年FDA批准599个新治疗剂,其中生物制品159个(27%),小分子药物440个(73%)。
  • 生物制品与小分子药物的中位开发时间分别为12.6年与12.7年(P=0.76),中位研发成本分别为30亿美元与21亿美元(P=0.39)。
  • 生物制品中位专利数14项、至生物类似药竞争时间20.3年,均高于小分子药物的3项和12.6年。

核心结论

  • 几乎没有证据支持生物制品应比小分子药物享有更长的市场独占期或价格谈判保护。
  • 由于差别待遇,美国法律似乎相对过度奖励生物制品的开发。

研究设计与样本

  • 证据综述,分析美国生物制品与小分子药物在开发时间、临床试验成功率、研发成本、专利保护、市场独占期、收入和治疗成本方面的近期数据。

主要发现

  • 2009-2023年FDA批准599个新治疗剂,其中生物制品159个(27%),小分子药物440个(73%)。
  • 中位开发时间生物制品12.6年(IQR 10.6-15.3年) vs 小分子药物12.7年(IQR 10.2-15.5年),P=0.76。
  • 生物制品在开发的每个阶段临床试验成功率均更高。
  • 中位专利数生物制品14项(IQR 5-24项) vs 小分子药物3项(IQR 2-5项),P<0.001;至生物类似药竞争的中位时间生物制品20.3年(IQR 16.9-21.7年) vs 小分子药物12.6年(IQR 12.5-13.5年)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Biologics approved by the US Food and Drug Administration (FDA) receive 12 years of guaranteed protection from biosimilar competition compared with 5 years of protection from generic competition for new small-molecule drugs. Under the 2022 Inflation Reduction Act, biologics are exempt from selection for Medicare price negotiation for 11 years compared with 7 years for small-molecule drugs. Congress codified these differing legal protections on the premise that biologics require more time and resources to develop and have weaker patent protection, necessitating additional protections for manufacturers to recoup their development costs and generate adequate returns on investment. OBJECTIVE: To review empirical evidence from the US experience with biologics to analyze the assumptions underlying longer periods of market exclusivity and protection from price negotiation compared with small-molecule drugs. EVIDENCE REVIEW: Recent data on development times, clinical trial success rates, research and development costs, patent protection, market exclusivity periods, revenues, and treatment costs of biologics vs small-molecule drugs were analyzed. FINDINGS: The FDA approved 599 new therapeutic agents from 2009-2023, of which 159 (27%) were biologics and 440 (73%) were small-molecule drugs. Median development times were 12.6 years (IQR, 10.6-15.3 years) for biologics vs 12.7 years (IQR, 10.2-15.5 years) for small-molecule drugs (P = .76). Biologics had higher clinical trial success rates at every phase of development. Median development costs were estimated to be $3.0 billion (IQR, $1.3 billion-$5.5 billion) for biologics and $2.1 billion (IQR, $1.3 billion-$3.7 billion) for small-molecule drugs (P = .39). Biologics were protected by a median of 14 patents (IQR, 5-24 patents) compared with 3 patents (IQR, 2-5 patents) for small-molecule drugs (P < .001). The median time to biosimilar competition was 20.3 years (IQR, 16.9-21.7 years) compared with 12.6 years (IQR, 12.5-13.5 years) for small-molecule drugs. Biologics achieved higher median peak revenues ($1.1 billion in year 13; IQR, $0.5 billion-$2.9 billion) than small-molecule drugs ($0.5 billion in year 8; IQR, $0.1 billion-$1.2 billion; P = .01) and had higher median revenues in each year following FDA approval. The median annual cost of treatment was $92 000 (IQR, $31 000-$357 000) for biologics and $33 000 (IQR, $4000-$177 000) for small-molecule drugs (P = .005). CONCLUSIONS AND RELEVANCE: There is little evidence to support biologics having longer periods of market exclusivity or protection from negotiation. As a result of differential treatment, US law appears to overly reward the development of biologics relative to small-molecule drugs.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Wouters OJ, Vogel M, Feldman WB, et al. Differential Legal Protections for Biologics vs Small-Molecule Drugs in the US. JAMA. 2024. PMID: 39585667. doi:10.1001/jama.2024.16911

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。